Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data01:16

Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data

Statistical inference techniques, paramount in hypothesis testing, differentiate into two broad categories: parametric and nonparametric statistics.
Parametric statistics, as the name suggests, assumes that data follow a specific distribution, often a normal distribution. This assumption enables robust hypothesis testing and estimation. Parametric methods, like the Student's t-test or Goodness-of-fit test, are frequently employed in biostatistics due to their robustness. For instance, comparing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Power Calculation for Non-inferiority Test Based on Linear Combination of Two Correlated Binary Endpoints.

Therapeutic innovation & regulatory science·2026
Same author

Controversial issues in clinical investigation of rare disease drug development.

Journal of biopharmaceutical statistics·2026
Same author

Switching Design for Assessment of Interchangeability in Biosimilar Studies.

Pharmaceutics·2026
Same author

Acupuncture for acute musculoskeletal pain in the emergency department and clinic: a pragmatic randomized trial.

Pain medicine (Malden, Mass.)·2025
Same author

Study Protocol: Single-Blinded, Controlled, Clinical Trial Evaluating the Feasibility of Spinal Cord Stimulation for Improving Neuropathic Pain and Rehabilitation Outcomes in Patients With Thoracic Spinal Cord Injury.

Neurosurgery practice·2025

Related Experiment Video

Updated: Jun 17, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Statistical methods for assessment of biosimilarity using biomarker data.

Shein-Chung Chow1, Qingshu Lu, Siu-Keung Tse

  • 1Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.

Journal of Biopharmaceutical Statistics
|January 16, 2010
PubMed
Summary

Assessing biosimilarity for biologics requires new statistical methods. This study proposes a probability-based criterion using biomarker data for evaluating follow-on biologic products against innovator biologics.

More Related Videos

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Related Experiment Videos

Last Updated: Jun 17, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Area of Science:

  • Biopharmaceutical science
  • Regulatory science
  • Statistical methodology

Background:

  • Current regulations lack abbreviated pathways for biologic license applications (BLA).
  • The U.S. Food and Drug Administration (FDA) is developing guidance for biosimilarity assessment.
  • Existing bioequivalence assessments use pharmacokinetic surrogate endpoints.

Purpose of the Study:

  • To derive statistical methods for assessing biosimilarity between biologic products.
  • To establish a probability-based criterion for biosimilarity using biomarker data.
  • To address the regulatory gap for abbreviated BLA pathways.

Main Methods:

  • Development of statistical methods based on a fundamental biosimilar assumption.
  • Utilization of biomarker data as a surrogate for clinical outcomes.
  • Application of a probability-based criterion for biosimilarity evaluation.

Main Results:

  • Statistical methods derived for biosimilarity assessment under proposed assumptions.
  • A framework for evaluating follow-on biologics using predictive biomarkers.
  • Foundation for draft guidance on biosimilarity assessment.

Conclusions:

  • Biomarker data can serve as a surrogate for clinical outcomes in biosimilarity assessment.
  • The proposed methods support the development of abbreviated BLA pathways.
  • Statistical rigor is essential for ensuring the safety and efficacy of follow-on biologics.